Production of De Novo Cardiomyocytes: Human Pluripotent Stem Cell Differentiation and Direct Reprogramming

By P. Burridge, G. Keller, Joseph D. Gold, Joseph C. Wu. Cell Stem Cell, 2012

653 citations recorded by the source corpus.

SUMMARY Cardiovascular disease is a leading cause of death worldwide. The limited capability of heart tissue to regenerate has prompted method developments for creating de novo cardiomyocytes, both in vitro and in vivo. Beyond uses in cell replacement therapy, patient-specific cardiomyocytes may find applications in drug testing, drug discovery, and disease modeling. Recently, approaches for generating cardiomyocytes have expanded to encompass three major sources of starting cells: human pluripotent stem cells (hPSCs), adult heart-derived cardiac progenitor cells (CPCs), and reprogrammed fibroblasts. We discuss state-of-the-art methods for generating de novo cardiomyocytes from hPSC and reprogrammed fibroblasts, highlighting potential applications and future challenges.

Subfields: Molecular Biology

View Paper: https://www.semanticscholar.org/paper/170755f537629e47e0cd0888fd4e000c90efabf5

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

Citations in the corpus

Braveheart, a long non-coding RNA required for cardiovascular lineage commitment (2013, background): “Stem cell models and the generation of specific cell types in vitro offer a potential avenue for studying diseases in a dish and ultimately for transplantation therapy (Burridge et al., 2012).”
Abnormal Calcium Handling Properties Underlie Familial Hypertrophic Cardiomyopathy Pathology in Patient-Specific Induced Pluripotent Stem Cells (2013, background): “First, as described by several other reports, both hESCCMs and iPSC-CMs are developmentally immature and are characterized by gene expression profiles similar to fetal cardiomyocytes, as well as lower levels of b-myosin than adult cardiomyocytes (Burridge et al., 2012; Cao et al., 2008; CarvajalVerg”
Redefining the in vivo origin of metanephric nephron progenitors enables generation of complex kidney structures from pluripotent stem cells. (2014, background): “These data also reveal differences in the developmental processes between the posteriorly located MM and the anteriorly located mesodermal tissues, such as the heart, which have been successfully induced from PSCs by way of the T state in the initial short period of differentiation (Burridge et al.,”
Distinct metabolic flow enables large-scale purification of mouse and human pluripotent stem cell-derived cardiomyocytes. (2013, background): “Pluripotent stem cells (PSCs) including embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) are potential sources for produc- tion of therapeutic cardiomyocytes (Burridge et al., 2012; Taka- hashi et al., 2007; Thomson et al., 1998).”